Funding for this research was provided by:
Text and Data Mining valid from 2019-08-30
Received: 14 June 2019
Accepted: 21 August 2019
First Online: 30 August 2019
Ethics approval and consent to participate
: The study was conducted in accordance with the Helsinki Declaration, approved by The Danish National Committee on Biomedical Research Ethics, amendment to protocol no. H-3-2009-139 [CitationRef removed]. All participants gave written, informed consent.
: Not applicable.
: The authors declare that they have no competing interest associated with this manuscript. PR reports having given lectures for Astra Zeneca, Novo Nordisk, Eli Lilly, Bayer and Boehringer Ingelheim, and has served as a consultant for AbbVie, Astra Zeneca, BMS, Eli Lilly, Boehringer Ingelheim, Astellas, Janssen, and Novo Nordisk, all fees given to Steno Diabetes Center Copenhagen, and has equity interest in Novo Nordisk. TV has nothing to disclose. BJvS is now employed at Novo Nordisk and has equity interest in Novo Nordisk. PGJ reports having received lecture fees from Novo Nordisk.